The association between proton pump inhibitor use and systemic anti-tumour therapy on survival outcomes in patients with advanced non-small cell lung cancer: A systematic review and meta-analysis

Review of 14 retrospective studies (n=13,709) found PPI use was correlated with an increased risk of mortality and disease progression vs non-use in patients with NSCLC on antitumour therapy (Mortality HR = 1.35, 95%CI 1.21-1.51, HR for progression or death = 1.50, 1.25-1.80).

SPS commentary:

Authors note that the mechanism of the association between PPI use and mortality risk in NSCLC patients is unclear, but suggest alteration of gut pH and microflora may impair uptake of cancer treatment and treatment response (e.g. when using tyrosine kinase inhibitor or immune checkpoint inhibitor therapy)

British Journal of Clinical Pharmacology